Immunome, Inc.
IMNM
$20.92
$0.211.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 3.21% | 21.61% | |||
| Gross Profit | -3.21% | -35.01% | |||
| SG&A Expenses | 10.47% | 8.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.53% | 19.10% | |||
| Operating Income | -4.53% | -29.39% | |||
| Income Before Tax | -21.66% | -32.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.66% | -32.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.66% | -32.40% | |||
| EBIT | -4.53% | -29.39% | |||
| EBITDA | -4.51% | -29.90% | |||
| EPS Basic | -12.72% | -30.95% | |||
| Normalized Basic EPS | 3.40% | -30.99% | |||
| EPS Diluted | -12.72% | -30.95% | |||
| Normalized Diluted EPS | 3.40% | -30.99% | |||
| Average Basic Shares Outstanding | 7.93% | 1.09% | |||
| Average Diluted Shares Outstanding | 7.93% | 1.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||